Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 236

Sort by

Sort Order Select

Journal Articles

Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs

Blood blood.2025029572.

https://doi.org/10.1182/blood.2025029572

Published: 2025

Includes: Supplemental data

Journal Articles

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2025-4598

Published: 2025

Journal Articles

Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network

Roman Hajek, Jiri Minarik, Stork Martin, Alexandra Jungova, Giselle Lostaunau Costa, Yuwei Wang, Solenn Salaun, Nolen J. Perualila, Guillaume Azarias, Markus Rückert

Blood (2025) 146 (Supplement 1): 4581.

https://doi.org/10.1182/blood-2025-4581

Published: 2025

Journal Articles

Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM)

Blood (2025) 146 (Supplement 1): 223.

https://doi.org/10.1182/blood-2025-223

Published: 2025

Journal Articles

More than IL-2: Optimizing feeder-free NK cell function through cytokine synergy

Maxima Warmuzová, Klára Baďurová, Zuzana Chyra, Daniela Gachová, Agáta Kubíčková, Jamal Alzubi, Michal Simicek, Tomas Jelinek, Jana Kotulová, Roman Hajek

Blood (2025) 146 (Supplement 1): 5966.

https://doi.org/10.1182/blood-2025-5966

Published: 2025

Journal Articles

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Blood (2025) 146 (Supplement 1): 494.

https://doi.org/10.1182/blood-2025-494

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Blood (2025) 146 (Supplement 1): 493.

https://doi.org/10.1182/blood-2025-493

Published: 2025

Journal Articles

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Blood (2025) 146 (Supplement 1): 5820.

https://doi.org/10.1182/blood-2025-5820

Published: 2025

Journal Articles

Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data

Blood (2025) 146 (Supplement 1): 1834.

https://doi.org/10.1182/blood-2025-1834

Published: 2025

Journal Articles

Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence

Ondrej Venglar, Viera Hrabcakova, Ondrej Soucek, Kamila Kutejova, David Žihala, Jana Mihalyova, Michaela Hornakova, Tereza Sevcikova, Lucie Broskevicova, Lenka Janska Vojtkova, Marek Borsky, Jakub Radocha, Pavel Zak, Michael Doubek, Tomas Kalina, Roman Hajek, David Belada, Frantisek Folber, Tomas Jelinek

Blood (2025) 146 (Supplement 1): 5721.

https://doi.org/10.1182/blood-2025-5721

Published: 2025

Journal Articles

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Blood (2025) 146 (Supplement 1): 5720.

https://doi.org/10.1182/blood-2025-5720

Published: 2025

Journal Articles

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

Blood (2025) 146 (Supplement 1): 3927.

https://doi.org/10.1182/blood-2025-3927

Published: 2025

Journal Articles

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

Blood (2025) 146 (Supplement 1): 2265.

https://doi.org/10.1182/blood-2025-2265

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Blood (2025) 146 (Supplement 1): 364.

https://doi.org/10.1182/blood-2025-364

Published: 2025

Journal Articles

Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network

Blood (2025) 146 (Supplement 1): 2803.

https://doi.org/10.1182/blood-2025-2803

Published: 2025

Journal Articles

Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2262.

https://doi.org/10.1182/blood-2025-2262

Published: 2025

Journal Articles

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Blood (2025) 146 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2025-4590

Published: 2025

Journal Articles

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4588.

https://doi.org/10.1182/blood-2025-4588

Published: 2025

Journal Articles

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Blood blood.2025030113.

https://doi.org/10.1182/blood.2025030113

Published: 2025

Includes: Supplemental data

Journal Articles

Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network

Markus Rückert, Guillaume Azarias, Mamta Garg, Ceri Bygrave, Hannah Belcher, Clare Hague, Kristina Bardenheuer, Wout Vekemans, Morten Salomo, Blanca Gros Otero, Nolen Perualila, Michel Van Speybroeck, Joris Diels, Vladimir Maisnar, Ivan Špička, Roman Hájek

Blood (2024) 144 (Supplement 1): 2388.

https://doi.org/10.1182/blood-2024-201692

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network

Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM)

More than IL-2: Optimizing feeder-free NK cell function through cytokine synergy

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data

Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network

Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only